Shares of Sanofi (NASDAQ:SNY – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $42.26 and last traded at $42.4420, with a volume of 52797 shares changing hands. The stock had previously closed at $42.50.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on SNY. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Morgan Stanley set a $52.00 price target on Sanofi in a research report on Friday, May 1st. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Sanofi has a consensus rating of “Hold” and a consensus price target of $51.00.
Get Our Latest Stock Report on Sanofi
Sanofi Stock Performance
Sanofi Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were paid a dividend of $2.4225 per share. This represents a yield of 559.0%. The ex-dividend date was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is currently 49.16%.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. Advisory Services Network LLC grew its stake in shares of Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares in the last quarter. Savant Capital LLC boosted its stake in Sanofi by 2.7% during the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after buying an additional 225 shares in the last quarter. Wesbanco Bank Inc. boosted its stake in Sanofi by 4.9% during the fourth quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after buying an additional 230 shares in the last quarter. IFG Advisory LLC boosted its stake in Sanofi by 2.7% during the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after buying an additional 244 shares in the last quarter. Finally, Cohen Investment Advisors LLC boosted its stake in Sanofi by 2.9% during the first quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock valued at $457,000 after buying an additional 263 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.
About Sanofi
Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
See Also
- Five stocks we like better than Sanofi
- 3 Space ETFs for a Timely Investment
- USA Rare Earth Just Moved Closer to Commercial Reality
- The AI Trade Is Getting Harder to Pick, But These 3 ETFs Take a Different Route
- 3 Hotel REITs Poised to Benefit from the World Cup
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
